Crown Bioscience launches HuScreen — a new high throughput service platform utilizing the largest available collection of PDX models
HuScreen will initially focus on popular indications such as colorectal, gastric, lung (small and non-small cell type), ovarian and breast cancer.
Crown Bioscience, a wholly owned subsidiary of Crown Bioscience International has launched HuScreen — a new translational oncology service platform utilizing CrownBio's fully characterized collection of patient-derived xenograft models (PDX).
"Given the high cost of drug development and the low rate of success of compounds advancing in the clinic, preclinical oncology research needs to be refined, with the development of better assays and models," said Jean Pierre Wery, president of Crown Bioscience.
With HuPrime, the largest commercially available portfolio of well-characterized and annotated PDX, now approaching 3,000 models over more than 70 clinical indications, CrownBio offers a collection large enough to be representative of the histological and genetic diversity seen in the patient population in ongoing clinical trials.
"Cancer is a heterogeneous disease, in which one drug will not work for all patients," said Henry Li, vice president of Translational Oncology at CrownBio. "The identification of predictive biomarkers and genetic signatures in the patient population could greatly facilitate stratification in the clinic, and increase the chances of success for new agents."
To improve the predictive power and cost effectiveness of preclinical studies using PDX models, CrownBio has now developed HuScreen a high throughput screening platform to assess the antitumour efficacy of candidate compounds using large cohorts of PDX models.
Tens of compounds can be tested as single agents or combination therapies on hundreds of PDX models in each HuScreen to rapidly assess population responses across more than 70 indications. "HuScreen can replicate the multitude of clinical trial designs in a preclinical setting, which will enable clients to make informed decisions on lead candidates and patient selection while reducing costs and time to market," said Li.
Thanks to the high level of characterization of all HuPrime PDX models, with all model data available in HuBase — CrownBio's online freely searchable database — HuScreen will be able to identify lead candidates, genetic signatures predictive of response, establish mechanisms of drug resistance, or reposition candidates that failed during late stage trials.
HuScreen will initially focus on popular indications such as colorectal, gastric, lung (small and non-small cell type), ovarian, and breast cancer, to name only a few; however, it will soon be expanded to cover more cancer types.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance